Phaos Technology is a Cayman Islands holding company whose only operating business is a Singapore microscopy assembler that listed Class A shares on NYSE American last November and has already spent most of the float rebuilding a going-concern story rather than scaling the product. The investment debate is not whether the microsphere optics work in a lab. The debate is whether a public Class A stub with one vote per share can survive a controlled dual-class structure, a collapsed commercial base, and a freshly approved reverse split plus authorized-share increase before cash runs out.
The latest fiscal year shows how far the listing failed to convert science into sales. Revenue fell to just over $104 thousand. That is a further drop from an already thin prior year, after customers delayed orders that management now assigns to the following fiscal year. The net loss widened past $4.8 million. Operating cash outflow exceeded $8.5 million. Year-end cash sat near $598 thousand. That is the post-offering reality. A primary raise priced at $4.00 a share was followed by a year in which cash left faster than orders arrived.
The counterargument is that the delay is timing, not demand, and that a fifteen-for-one consolidation plus a larger authorized share pool gives the board tools to stay listed and fund another cycle. That reading only works if delayed orders convert at a scale that matters and if new paper is not the entire equity story. Class B holders keep twenty votes a share and those shares are not convertible. The next prints have to show whether Phaos is a microscopy company that happens to be small, or a listing vehicle whose residual claim is the option on another raise.